Dendreon Corp fka DNDNQ

[bobrmd]

There is an assumption among posters that unless favorable patient selection takes place or more favorable aipc patients enter the trial, the impact trial will fail. Its not necessarily true. Posters seem to jump on the bandwagon and assume the theoretical but unproven argument that immunotherapy works best in earlier diseaseis is gospel/. That is just a hypothesis. I feel comfortable with the present patient selection As long as the placebo group and treatment groups are balanced. In the meantime we just sit back and await more data.